All In Biotech

Drug Trial Radar · NCT00405808

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities

Last checked: Nov 20, 2026Latest source record: Jan 26, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 2,666 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,666

Actual

Start

Dec 2006

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with impaired fasting blood glucose and with or without associated comorbidities. Main Secondary objectives: To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic parameters and lipid parameters. To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.

Conditions

  • Obesity

Interventions

  • RimonabantDrug

    Once daily in the morning

  • PlaceboDrug

    Once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels.Time frame: From baseline to end of treatment

Locations

27 sites in 27 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Vienna, Austria

  • Sanofi-Aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Sofia, Bulgaria

  • Sanofi-Aventis Administrative Office

    Laval, Canada

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Cairo, Egypt

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Kallithea, Greece

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Dublin, Ireland

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Vilnius, Lithuania

  • Sanofi-Aventis Administrative Office

    Luxembourg, Luxembourg

  • Sanofi-Aventis Administrative Office

    Col. Coyoacan, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Lysaker, Norway

  • Sanofi-Aventis Administrative Office

    Porto Salvo, Portugal

  • Sanofi-Aventis Administrative Office

    Bratislava, Slovakia

  • Sanofi-Aventis Administrative Office

    Barcelona, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis Administrative Office

    Guildford Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.